ATE430732T1 - Piperidinderivate und medikamente die diese derivate als aktiven wirkstoff enthalten - Google Patents

Piperidinderivate und medikamente die diese derivate als aktiven wirkstoff enthalten

Info

Publication number
ATE430732T1
ATE430732T1 AT01955627T AT01955627T ATE430732T1 AT E430732 T1 ATE430732 T1 AT E430732T1 AT 01955627 T AT01955627 T AT 01955627T AT 01955627 T AT01955627 T AT 01955627T AT E430732 T1 ATE430732 T1 AT E430732T1
Authority
AT
Austria
Prior art keywords
derivatives
diseases
medications
contain
active ingredients
Prior art date
Application number
AT01955627T
Other languages
English (en)
Inventor
Hisao Nakai
Kat Kishikawa
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE430732T1 publication Critical patent/ATE430732T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
AT01955627T 2000-08-11 2001-08-09 Piperidinderivate und medikamente die diese derivate als aktiven wirkstoff enthalten ATE430732T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000243881 2000-08-11
JP2000357517 2000-11-24
PCT/JP2001/006861 WO2002014280A1 (en) 2000-08-11 2001-08-09 Piperidine derivatives and drugs containing these derivatives as the active ingredient

Publications (1)

Publication Number Publication Date
ATE430732T1 true ATE430732T1 (de) 2009-05-15

Family

ID=26597806

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01955627T ATE430732T1 (de) 2000-08-11 2001-08-09 Piperidinderivate und medikamente die diese derivate als aktiven wirkstoff enthalten

Country Status (21)

Country Link
US (2) US7109342B2 (de)
EP (1) EP1308440B1 (de)
JP (1) JP3433752B2 (de)
KR (1) KR100586765B1 (de)
CN (1) CN1203058C (de)
AT (1) ATE430732T1 (de)
AU (2) AU7773801A (de)
BR (1) BR0113167A (de)
CA (1) CA2418313C (de)
CZ (1) CZ301834B6 (de)
DE (1) DE60138628D1 (de)
ES (1) ES2325353T3 (de)
HU (1) HUP0303673A3 (de)
IL (2) IL154231A0 (de)
MX (1) MXPA03001276A (de)
NO (1) NO324869B1 (de)
NZ (1) NZ524050A (de)
PL (1) PL205307B1 (de)
RU (1) RU2275359C2 (de)
TW (1) TWI232858B (de)
WO (1) WO2002014280A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094321A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
WO2002094320A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Therapeutic compositions for repairing chondropathy
DE60335788D1 (de) * 2002-02-08 2011-03-03 Ono Pharmaceutical Co Piperidinderivatverbindungen und arzneimittel, die diese verbindungen als wirkstoff enthalten
AU2003207180A1 (en) * 2002-02-08 2003-09-02 Ono Pharmaceutical Co., Ltd. Piperidine derivative compounds and drugs containing the compounds as the active ingredient
WO2005007161A1 (ja) * 2003-07-17 2005-01-27 Santen Pharmaceutical Co., Ltd. ピペリジン誘導体を有効成分とする掻痒治療剤
WO2005023253A1 (en) 2003-09-05 2005-03-17 Altana Pharma Ag Use of pde4 inhibitors for the treatment of diabetes mellitus
US20070078120A1 (en) * 2003-10-21 2007-04-05 Hitoshi Ban Novel piperidine derivative
CN1905881A (zh) * 2003-11-26 2007-01-31 阿托恩药品公司 二胺和亚氨二醋酸异羟肟酸衍生物
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
AU2006222060B2 (en) * 2005-03-08 2011-09-01 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
ES2636596T3 (es) * 2012-11-20 2017-10-06 Biogen Ma Inc. Agentes moduladores de S1P y/o ATX
EP3096749B1 (de) * 2014-01-24 2019-05-15 Celgene Corporation Verfahren zur behandlung von adipositas mit apremilast
CN113121417A (zh) * 2019-12-30 2021-07-16 苏州盛迪亚生物医药有限公司 一种新型哌啶衍生物及其药物用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602173A (en) 1992-04-02 1997-02-11 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
GB9305175D0 (en) * 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
IL112099A (en) * 1993-12-23 1999-07-14 Ortho Pharma Corp N-oxides of 4-arylpiperazines and 4-arylpiperidines and pharmaceutical compositions containing them
FR2753706B1 (fr) * 1996-09-20 1998-10-30 Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
US7649095B2 (en) 2010-01-19
RU2275359C2 (ru) 2006-04-27
KR20030021261A (ko) 2003-03-12
CA2418313A1 (en) 2003-02-05
IL154231A0 (en) 2003-07-31
EP1308440A1 (de) 2003-05-07
ES2325353T3 (es) 2009-09-02
HUP0303673A2 (hu) 2004-03-01
NO324869B1 (no) 2007-12-17
WO2002014280A1 (en) 2002-02-21
EP1308440A4 (de) 2006-08-09
CA2418313C (en) 2008-09-23
EP1308440B1 (de) 2009-05-06
US20040044036A1 (en) 2004-03-04
NO20030639L (no) 2003-04-09
AU2001277738B2 (en) 2006-10-05
CZ2003402A3 (cs) 2003-12-17
CN1468219A (zh) 2004-01-14
US7109342B2 (en) 2006-09-19
CZ301834B6 (cs) 2010-07-07
NZ524050A (en) 2005-07-29
KR100586765B1 (ko) 2006-06-08
BR0113167A (pt) 2003-06-24
US20060189656A1 (en) 2006-08-24
AU7773801A (en) 2002-02-25
TWI232858B (en) 2005-05-21
MXPA03001276A (es) 2003-09-05
HUP0303673A3 (en) 2010-04-28
CN1203058C (zh) 2005-05-25
PL205307B1 (pl) 2010-04-30
IL154231A (en) 2008-12-29
PL361360A1 (en) 2004-10-04
DE60138628D1 (de) 2009-06-18
JP3433752B2 (ja) 2003-08-04
NO20030639D0 (no) 2003-02-07

Similar Documents

Publication Publication Date Title
DE60138628D1 (de) Piperidinderivate und medikamente die diese derivate als aktiven wirkstoff enthalten
ATE450534T1 (de) Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung
IL148384A0 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
DE60115623D1 (de) Glucopyranosyloxy-benzylbenzen-derivate, medizinische zusammensetzung und zwischenprodukte für die herstellung der derivate
GB0318447D0 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
MXPA06011194A (es) Tiadiazolidinonas como inhibidores de gsk-3.
NO20051209L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
GB0225474D0 (en) Therapeutic agents
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
GB0223038D0 (en) Therapeutic compounds
SE0102764D0 (sv) Compounds
TNSN04082A1 (en) N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
EA200401114A2 (ru) Замещённые гидроксиэтиламины
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DK1463735T3 (da) Imidazo-2,1-B -1,3,4-thiadiazol-sulfonamider
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
CY1111900T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα ν-μεθυλ-d-ασπαρτικων (nmda)
NO20013544L (no) Middel for å behandle Parkinsons sykdom samt anvendelse derav

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties